Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Catanil
- Development stage
- Unknown
- Lead developer
- Oak-Faith Pharmaceutical Resources
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Catanil** is an oral fixed-dose cold and catarrh-relief syrup marketed by Oak-Faith Pharma in Nigeria. Each 5 mL contains paracetamol 125 mg and chlorpheniramine maleate 2 mg. Paracetamol provides analgesic and antipyretic activity, while chlorpheniramine is a first-generation H1 antihistamine with anticholinergic activity that relieves allergy-associated rhinorrhea, sneezing, itching, and watery eyes. The product is indicated for common-cold symptoms, catarrh, nasal blockage or discharge, respiratory-allergy symptoms, fever, and associated aches and pains. ([oak-faithpharma.com](https://oak-faithpharma.com/products/))
- Brand names
- Catanil
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Catanil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Catanil.